LCP-tacrolimus QD + MMF BID
ApprovedSmall molecule
LCP-tacrolimus QD + MMF BID is one of 33 small molecule programs targeting Liver Transplant. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
353 competitors in Liver Transplant
#DrugCompanyPhaseTrials
1LCP-tacrolimus QD + MMF BID
UUniversity Hospital, Limoges
Approved
Vemlidy
GileadPreclinical
Octreotide
Johnson & JohnsonPreclinical
Beyfortus
BeiGenePreclinical
Myfortic
NovartisPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Myfortic
NovartisPreclinical
Cyklokapron
AAmring
Preclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Valcyte
EEngelhard Arzneimittel GmbH & Co.KG
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LCP-tacrolimus QD + MMF BID. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity Hospital, Limoges